SCHEMBL2935514

SCHEMBL2935514

Cc1ccc(C(=O)NC[C@H](NC(=O)c2cnccn2)C(=O)NCCC(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
CTSL P07711 1/20 0.46
LONP1 P36776 9/20 0.46
PSMB5 P28074 6/20 0.45
PSMB11 A5LHX3 5/20 0.45
PSMA7 O14818 5/20 0.45
PSMB1 P20618 5/20 0.45
PSMA1 P25786 5/20 0.45
PSMA2 P25787 5/20 0.45
PSMA3 P25788 5/20 0.45
PSMA4 P25789 5/20 0.45
PSMB8 P28062 5/20 0.45
PSMB9 P28065 5/20 0.45
PSMA5 P28066 5/20 0.45
PSMB4 P28070 5/20 0.45
PSMB6 P28072 5/20 0.45
PSMB10 P40306 5/20 0.45
PSMB3 P49720 5/20 0.45
PSMB2 P49721 5/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931864 0.87 KMT2A (0.57) SMN1; SMN2PSMB5PSMB8NPC1RAB9A
SCHEMBL2926141 0.85 RAB9A (0.48) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL2935509 0.84 SMN1; SMN2 (0.46) POLBSMN1; SMN2CTSLLONP1PSMB5
SCHEMBL2927699 0.83 NPC1 (0.53) POLBSMN1; SMN2CTSLPSMB5PSMB8
SCHEMBL609385 0.83 SMN1; SMN2 (0.52) SMN1; SMN2CTSLLONP1PSMB5PSMB11
SCHEMBL2936754 0.83 LONP1 (0.69) LONP1PSMB5PSMB11PSMA7PSMB1
SCHEMBL2929287 0.82 NPC1 (0.48) POLBSMN1; SMN2PSMB5NPC1RAB9A
SCHEMBL2930534 0.82 GRN (0.53) SMN1; SMN2PSMB5NPC1RAB9AMEN1
SCHEMBL2931810 0.82 NPC1 (0.45) POLBSMN1; SMN2PSMB5NPC1RAB9A
SCHEMBL2935265 0.82 NPC1 (0.56) POLBSMN1; SMN2PSMB5NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US claimed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP claimed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US claimed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US claimed
US-8283367-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2012-10-09 US disclosed
EP-1846424-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-01-27 EP disclosed
US-20090075936-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-03-19 US disclosed
US-7468383-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2008-12-23 US disclosed
US-20060189806-A1 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189806-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 POLB 836/4885SMN1; SMN2 1069/4885CTSL 1679/4885
US-20090075936-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 POLB 836/4885SMN1; SMN2 1069/4885CTSL 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.